Overexpression of human carcinoma-associated antigen in urothelial carcinoma of the bladder

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 7, 2004, Pages 785-787

  Yao, Jorge L ^a   Bourne, Patricia A ^a   Yang, Qi ^a   Lei, Junyi ^a   Di Sant'Agnese, P Anthony ^a   Huang, Jiaoti ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MUCIN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CONTROLLED STUDY; CYSTECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; UROTHELIUM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 3042744008     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Codington JF, Cooper AG, Miller DK, et al. Isolation and partial characterization of an epiglycanin-like glycoprotein from a new non-strain-specific subline of TA3 murine mammary adenocarcinoma. J Natl Cancer Inst. 1979;63:153-161.
2. Talor JA, Goluboff ET, Holub W, et al. The human carcinoma antigen: a new biomarker for prostate cancer. J Urol. 1999;161(suppl):209.
3. Codington JF, Bhavanandan VP, Bloch KJ, et al. Antibody to epiglycanin and radioimmunoassay to detect epiglycanin-related glycoproteins in body fluids of cancer patients. J Natl Cancer Inst. 1984;73:1029-1037.
4. Codington JF, Haavik S, Nikrui N, et al. Immunologic quantitation of the carcinoma specific human carcinoma antigen in clinical samples. Cancer. 2002;94:803-813.
5. Li R, Bourne PA, di Sant'Agnese PA, Huang J. Frequent expression of human carcinoma-associated antigen (HCA), a mucin-type glycoprotein, by cells of prostatic carcinoma. Mod Pathol. 2003;16:159A.
6. Cooper AG, Codington JF, Miller DK, Brown MC. Loss of strain specificity of the TA3-St subline: evidence for the role of epiglycanin in mouse allogeneic tumor growth. J Natl Cancer Inst. 1979;63:163-169.
7. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2003;15:227-233.
8. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology. 2003;61:109-118.
9. Tiguert R, Fradet Y. New diagnostic and prognostic tools in bladder cancer. Curr Opin Urol. 2002;12:239-243.
10. Fradet Y, Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt™ Can J Urol. 1997;4:400-405.
11. Olsson H, Zackrisson B. ImmunoCyt™ a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol. 2001;35:280-282.
12. Dodd J, Tyler JP, Crandon AJ, et al. The value of the monoclonal antibody (cancer antigen 125) in serial monitoring of ovarian cancer: a comparison with circulating immune complexes. Br J Obstet Gynaecol. 1985;92:1054-1060.
13. Barak M, Steiner M, Finkel B, Abrahamson J, Antal S, Gruener N. CA-15.3, TPA and MCA as markers for breast cancer. Eur J Cancer. 1990;26:577-580.
14. Rasoul-Rockenschaub S, Zielinski CC, Kubista E, et al. Diagnostic value of mucin-like carcinoma-associated antigen (MCA) in breast cancer. Eur J Cancer Clin Oncol. 1989;25:1067-1072.